Cybin Inc. Reports Strong Growth and Progress in Mental Healthcare Innovations

Revolutionizing Mental Healthcare: Cybin Inc. Conference Call Overview

Revolutionizing Mental Healthcare: Cybin Inc.'s Innovative Drug Development

Global Psychedelic Week 2025: Uniting the World in Psychedelic Conversation

Revolutionizing Mental Healthcare: Cybin Inc. to Present at 2025 Milken Institute Future of Health Summit

Cybin Inc. Announces $175M Direct Offering for Mental Health Treatment Development

Celebrate the Transformative Power of Psychedelics at Global Psychedelic Week 2025

Global Psychedelic Week 2025: A Worldwide Exploration of Psychedelic Therapies and Perspectives

Advancements in Preservative-Free Ketamine Therapies by NRx Pharmaceuticals

FDA Approval Secured for Preservative-Free Ketamine: NRx Pharmaceuticals Expands Market Opportunity

Uniting the World: Global Psychedelic Week 2025

Advancements and Milestones in Neuropsychiatry Drug Development by Cybin Inc.

Fireside Chat at TD Cowen's Summit with Cybin Inc. Executives

Advancements in Mental Health Treatments: NRx Pharmaceuticals and Cybin Inc. Acquisitions and Developments

Cybin Inc. Chief Business Officer to Speak at H.C. Wainwright Conference

Fireside Chat with Cybin Inc.'s CMO at Cantor Global Healthcare Conference

Leadership Changes and Treatment Advancements in Mental Health Companies

Advancing Psilocybin Therapy: Psylutions Supports Rescheduling Efforts

Empowering Growth for Ketamine & TMS Clinics: Strategic Partnership Announcement

Cybin Inc. Receives Approval for Phase 3 Study of CYB003 in Australia